Skip to main content

Abaxis, LamdaGen Teaming Up to Combine POC Platform with Plasmon Resonance Biosensing

Premium

Point-of-care device manufacturer Abaxis and biosensor firm LamdaGen said this week that they have entered into an R&D agreement aiming to integrate LamdaGen's plasmonic ELISA technology on Abaxis's rotor-based POC platforms.

If the integration proves viable, the agreement would enable Abaxis to multiplex a variety of markers on its rotor-based system, Abaxis CEO Clint Severson said in a statement.

"Both medical and veterinary customers will be able to simultaneously analyze for chemistry parameters as well as for infectious disease, hormones and a wide range of other markers on the same rotor," he said. "The ability to unify both diagnostic systems
onto our existing rotor will greatly expand Abaxis’ global diagnostic offerings.”

LamdaGen's biosensor platform is based on localized surface plasmon resonance, offering quantitative results and detection levels in the femtomolar range.

Financial and other terms of the agreement were not disclosed.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.